Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 13.40 is 68% above its 5-year average of 8.00, near the high end of its 5-year range (0.00–15.31).
As of the fiscal period ended Tuesday, June 30, 2026. 26.20% above its 12-month average of 10.62.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.40.
QUICK RATIO (ACID-TEST)
13.40
QUICK RATIO (ACID-TEST) AVG TTM
10.62
QUICK RATIO (ACID-TEST) AVG 3Y
10.34
QUICK RATIO (ACID-TEST) AVG 5Y
8.00
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.20%
CURRENT VS 3Y AVG
+29.62%
CURRENT VS 5Y AVG
+67.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.15
median of 703 covered companies
CURRENT VS SECTOR MEDIAN
+325.32%
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$116.34M
Quick Ratio (Acid-Test)
13.40
TTM Avg
10.62
3Y Avg
10.34
5Y Avg
8.00
Market Cap
$116.25M
Quick Ratio (Acid-Test)
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$116.59M
Quick Ratio (Acid-Test)
2.39
TTM Avg
3.50
3Y Avg
2.69
5Y Avg
1.97
Market Cap
$116.89M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.40
3Y Avg
1.60
5Y Avg
1.70
Market Cap
$115.36M
Quick Ratio (Acid-Test)
1.31
TTM Avg
1.18
3Y Avg
1.49
5Y Avg
3.22
Market Cap
$117.53M
Quick Ratio (Acid-Test)
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$114.08M
Quick Ratio (Acid-Test)
11.47
TTM Avg
9.04
3Y Avg
10.96
5Y Avg
10.73
Market Cap
$118.99M
Quick Ratio (Acid-Test)
13.31
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
Market Cap
$111.14M
Quick Ratio (Acid-Test)
0.65
TTM Avg
1.74
3Y Avg
2.55
5Y Avg
2.19
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $116.34M | 13.40 | 10.62 | 10.34 | 8.00 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.25M | 3.36 | 3.23 | 4.24 | 6.08 |
| Genelux Corporation (GNLX)vs › | $116.59M | 2.39 | 3.50 | 2.69 | 1.97 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.89M | 1.98 | 1.40 | 1.60 | 1.70 |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.36M | 1.31 | 1.18 | 1.49 | 3.22 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | 6.49 | 6.44 | 8.52 | 8.53 |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | 11.47 | 9.04 | 10.96 | 10.73 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | 13.31 | 17.30 | 10.78 | 9.73 |
| BGM Group Ltd. (BGM)vs › | $111.14M | 0.65 | 1.74 | 2.55 | 2.19 |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | 0.18 | 2.21 | 2.68 | 2.62 |
Quick Ratio
13.40
Excludes inventory
Current Ratio
13.40
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 13.40 |
| 2026-03-31 | 15.02 |
| 2025-12-31 | 8.50 |
| 2025-09-30 | 8.73 |
| 2025-06-30 | 7.43 |
| 2025-03-31 | 8.84 |
| 2024-12-31 | 11.59 |
| 2024-09-30 | 15.31 |
| 2024-06-30 | 10.43 |
| 2024-03-31 | 8.64 |
| 2023-12-31 | 8.15 |
| 2023-09-30 | 6.54 |
| 2023-06-30 | 11.78 |
| 2023-03-31 | 13.69 |
| 2022-12-31 | 1.88 |
| 2022-09-30 | 3.38 |
| 2022-06-30 | 6.63 |
| 2022-03-31 | 3.99 |
| 2021-12-31 | 3.99 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
